Magnus Life Science Announces Recommendation for Orphan Designation
EMA’s Committee for Orphan Medicinal Products recommends Magnus Growth Therapy for Placental Insufficiency for Orphan Designation
Magnus Life Science announces that the European Medicines Agency (EMA)’s Committee for Orphan Medicinal Products (COMP) has reached a positive decision on recommending orphan designation to Magnus Growth’s novel therapy to treat placental insufficiency. Placental insufficiency affects around 3.2% of all pregnancies (nearly 170,000 babies annually in the EU), usually becoming apparent during the second half of pregnancy when detected at routine ultrasound scans. Placental insufficiency causes fetal growth restriction where babies may stop growing in the womb. Babies born from pregnancies with placental insufficiency are not only at increased risk of perinatal death or complications such as cerebral palsy, but very typically there are long term consequences for their health which include diabetes and cardiovascular disease. There is no treatment.
Dr Anna David, Head of Magnus Growth and Reader and Consultant in Obstetrics and Maternal Fetal Medicine UCL Institute for Women's Health, University College London, said: “Research and development of obstetric medicines still receives minimal attention from the pharmaceutical industry. Placental insufficiency is an important condition with a significant unmet medical need. Sadly most affected babies either die in the womb are delivered prematurely and have long-term health consequences. A successful treatment could prevent still-births and neonatal death saving thousands of lives.”
Other news from the department research and development
